08/13/2025
3:26 PM | Jade Biosciences, Inc. (Filer)
Jade Biosciences (Filer)
| Form 8-A12B/A | |
07/29/2025
12:46 PM | Jade Biosciences, Inc. (Subject)
Jade Biosciences (Subject)
VANGUARD GROUP INC (Filed by)
| Form SCHEDULE 13G | |
07/17/2025
7:12 PM | BlackRock, Inc. (Filed by)
Jade Biosciences, Inc. (Subject)
Jade Biosciences (Subject)
| Form SCHEDULE 13G | |
07/14/2025
6:10 PM | Dahms Bradford D. (Reporting)
Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
07/14/2025
6:12 PM | Dahms Bradford D. (Reporting)
Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
07/01/2025
6:08 AM | Jade Biosciences, Inc. (Filer)
Jade Biosciences (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/25/2025
4:31 PM | Atlas Venture Associates XII, L.P. (Reporting)
Jade Biosciences, Inc. (Subject)
Jade Biosciences (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/25/2025
4:37 PM | Atlas Venture Fund XII, L.P. (Reporting)
Jade Biosciences, Inc. (Subject)
Jade Biosciences (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/24/2025
3:59 PM | Atlas Venture Associates XII, L.P. (Reporting)
Jade Biosciences, Inc. (Subject)
Jade Biosciences (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/24/2025
4:03 PM | Atlas Venture Fund XII, L.P. (Reporting)
Jade Biosciences, Inc. (Subject)
Jade Biosciences (Subject)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/20/2025
3:23 PM | Deep Track Capital, LP (Filed by)
Jade Biosciences, Inc. (Subject)
Jade Biosciences (Subject)
| Form SCHEDULE 13G | |
Get the Latest News and Ratings for JBIO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Jade Biosciences and its competitors with MarketBeat's FREE daily newsletter. |
06/06/2025
9:03 AM | FMR LLC (Filed by)
Jade Biosciences, Inc. (Subject)
Jade Biosciences (Subject)
| Form SCHEDULE 13G | |
05/05/2025
8:43 AM | Frazier Life Sciences Public Fund, L.P. (Filed by)
Jade Biosciences, Inc. (Subject)
Jade Biosciences (Subject)
| Form SCHEDULE 13G | |
05/01/2025
5:31 PM | Fairmount Funds Management LLC (Filed by)
Jade Biosciences, Inc. (Subject)
Jade Biosciences (Subject)
| Form SCHEDULE 13D | |
05/01/2025
4:44 PM | Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
Klein Lawrence Otto (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:51 PM | Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
Lavelle Erin (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:58 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
Kiselak Tomas (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
5:00 PM | DOBMEIER ERIC (Reporting)
Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2025
5:07 PM | CAIN CHRISTOPHER W. (Reporting)
Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2025
5:10 PM | Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
Klein Lawrence Otto (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2025
5:15 PM | Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
Lavelle Erin (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2025
5:16 PM | Fairmount Funds Management LLC (Reporting)
Fairmount Healthcare Fund II L.P. (Reporting)
Harwin Peter Evan (Reporting)
Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
Kiselak Tomas (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
05/01/2025
4:21 PM | Frohlich Tom (Reporting)
Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:22 PM | Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
Quick Jonathan (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:27 PM | Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
King Andrew James (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:30 PM | Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
Kocinsky Hetal (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:32 PM | Balta Elizabeth (Reporting)
Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:39 PM | DOBMEIER ERIC (Reporting)
Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
4:41 PM | CAIN CHRISTOPHER W. (Reporting)
Jade Biosciences, Inc. (Issuer)
Jade Biosciences (Issuer)
| Form 3
Initial statement of beneficial ownership of securities | |
05/01/2025
3:22 PM | Jade Biosciences, Inc. (Filer)
Jade Biosciences (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/25/2025
3:30 PM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
04/23/2025
3:37 PM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/21/2025
7:07 AM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/09/2025
3:20 PM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
04/09/2025
6:00 AM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/09/2025
6:01 AM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
04/07/2025
7:39 AM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
04/07/2025
7:42 AM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
04/07/2025
7:46 AM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
03/27/2025
6:30 AM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/26/2025
3:54 PM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
New law could create $3.7 trillion tsunami. (Ad) During a meeting in Washington D.C., Jeff Brown discovered a bold initiative.
He calls it “President Trump’s Project MAFA,” and it could soon return America to a “new” gold standard.
The Trump administration, Wall Street, and Silicon Valley are all pushing it forward. The President himself calls the plan “incredible.”
Already, it’s helping small plays jump as high as 300%, 318%, 520%, and even 600%. You can watch it right here. |
03/25/2025
11:15 PM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form EFFECT | |
03/25/2025
3:25 PM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form 424B3 | |
03/24/2025
9:45 AM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form S-4/A | |
03/14/2025
4:16 PM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form S-4/A | |
03/03/2025
3:45 PM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
02/24/2025
8:57 AM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form S-4/A | |
01/24/2025
3:17 PM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
01/22/2025
7:45 AM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form S-4/A | |
01/13/2025
4:24 PM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
12/03/2024
5:27 AM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form S-4
Registration statement under Securities Act of 1933 | |
11/18/2024
4:29 PM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
10/31/2024
3:55 PM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
10/31/2024
3:55 PM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
10/31/2024
3:57 PM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
10/31/2024
3:57 PM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
10/31/2024
8:27 AM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/31/2024
8:29 AM | Aerovate Therapeutics, Inc. (Subject)
Jade Biosciences (Subject)
| Form 425 | |
10/17/2024
3:59 PM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
10/10/2024
4:04 PM | Aerovate Therapeutics, Inc. (Filer)
Jade Biosciences (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
MarketBeat All Access